SRC and metabolic dysfunction-associated steatotic liver disease: A recent study by Elsayed et al. (2021) has found that administration of a SRC specific inhibitor, Dasatinib, can effectively prevent the progression of NAFLD in mice fed a Western diet (WD) for 16 weeks.